Latest news and press releases about Nkarta, Inc. (NKTX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as w...
Price
| Price | $2.87 |
| Market Cap | $205M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.01 |
| EV / EBITDA | -2.60 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -39.64% |
| Return on Invested Capital | -41.15% |
| Return on Assets | -34.75% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALEC · APLT · CYBN · ELTX · FATE · FBRX · MOLN
Explore sector: Healthcare · Biotechnology
More sections of NKTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks